(Q77751582)

English

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group

scientific article published on 01 December 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

phase III clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

author name string

Içli F

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Aykan F

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Uner A

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Demirkazik A

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Ozet A

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Ozgüroğlu M

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Taş F

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Akbulut H

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Firat D

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

publication date

1 December 1998

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

83

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

2475-2480

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Chemotherapy of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Phase II Trial of Etoposide (V), Adriamycin (A), and Cisplatinum (P) in Patients with Metastatic Gastric Cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF)

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Nativity, complications, and pathology are determinants of surgical results for gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819981215%2983%3A12%3C2475%3A%3AAID-CNCR10%3E3.0.CO%3B2-H

21 January 2018

Identifiers

10.1002/(SICI)1097-0142(19981215)83:12<2475::AID-CNCR10>3.0.CO;2-H

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9874451%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q77751582&oldid=1584731243"